History | Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia | Guidance | NICE

History

Documents created during the development process.

Other information

Background information

TA29 Leukaemia (lymphocytic) - fludarabine: review decision - December 2013 information
TA29 Leukaemia (lymphocytic) - fludarabine: Appendix A - decision paper presented to the Institute's Guidance Executive
TA29 Leukaemia (lymphocytic) - fludarabine: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 106 KB)

Published:

20 December 2013
TA29 Leukaemia (lymphocytic) - fludarabine: review proposal - October 2013 information
Appendix A: provisional matrix of stakeholders
Appendix A: provisional matrix of stakeholders (PDF 104 KB)

Published:

21 October 2013
Appendix B: proposal paper presented to the Institute's Guidance Executive
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 270 KB)

Published:

21 October 2013
Review decision information
Review proposal information
Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Cost-effectiveness annexe information
Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Cost-effectiveness annexe (PDF 32 KB)

Published:

25 September 2001
Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Effectiveness annexe information
Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Effectiveness annexe (PDF 126 KB)

Published:

25 September 2001
Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia - HTA report (main) information
Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia - HTA report (main) (PDF 285 KB)

Published:

25 September 2001